American Shared Hospital Services

American Shared Hospital Services(AMS)股票分析

$1.265

-0.015 (-1.20%)收盘时

Loading chart…
最高
1.310
开盘
1.310
成交量加权均价
1.27
成交量
6.57K
市值
20.46M
最低
1.250
成交额
8.37K
企业价值/息税折旧摊销前利润(TTM)
0.00

American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The Company provides radiation therapy services both domestically and internationally.

ashs.com

AI 分析 of American Shared Hospital Services (AMS)

买入

American Shared Hospital Services (AMS) is currently trading at $1.28, with a low RSI of 31.235 indicating it is oversold. The company reported a significant revenue growth of 19.2% year-over-year in Q2 2026, reaching $8.4 million, which shows strong operational performance. Additionally, the stock has a forward P/E ratio of 44.64, suggesting growth potential despite current losses. The main risk is the negative net income, which was -$998,000 in Q2 2026, but the improving cash flow and revenue growth provide a solid foundation for recovery.

估值指标

American Shared Hospital Services(AMS)当前预期市盈率为 44.64,5 年平均预期市盈率为 13.44。

预期市盈率

高估
5 年均值 P/E
13.44
当前P/E
44.64
高估
39.00
低估
-12.12

预期 EV/EBITDA

严重低估
5 年均值 EV/EBITDA
0.00
当前EV/EBITDA
0.00
高估
0.00
低估
0.00

预期市销率

低估
5 年均值 P/S
0.48
当前P/S
0.00
高估
0.80
低估
0.16

Alphio AI 对 AMS 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%AMS

$3.00

情景价格

基

基准

基准 · 50%AMS

$2.96

情景价格

悲

悲观

悲观 · 25%AMS

$2.19

情景价格

事件时间线

2025-12-01 (ET)

05:29:00

JPMorgan Downgrades ams OSRAM to Underweight, Price Target Cut to CHF 5.35

2025-11-13 (ET)

07:04:59

American Shared Hospital Announces Q3 EPS of 0c Compared to (3c) Last Year

2025-08-13 (ET)

07:07:11

American Shared Hospital reports Q2 EPS (4c) vs. 55c last year

2025-05-15 (ET)

07:02:10

American Shared Hospital reports Q1 EPS (10c) vs 2c last year

2025-04-04 (ET)

07:04:18

American Shared Hospital appoints Gary Delanois as CEO

资讯

AMS 常见问题 —— 由 Alphio AI 解答

American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The Company provides radiation therapy services both domestically and internationally. It operates in the Industrials sector (SERVICES-MEDICAL LABORATORIES industry).

American Shared Hospital Services (AMS) is currently trading at $1.28, with a low RSI of 31.235 indicating it is oversold. The company reported a significant revenue growth of 19.2% year-over-year in Q2 2026, reaching $8.4 million, which shows strong operational performance. Additionally, the stock has a forward P/E ratio of 44.64, suggesting growth potential despite current losses. The main risk is the negative net income, which was -$998,000 in Q2 2026, but the improving cash flow and revenue growth provide a solid foundation for recovery.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易